Acute Myeloid Leukemia Whole Blood

About Acute Myeloid Leukemia Whole Blood

Acute Myeloid Leukemia Whole Blood for Haematologic Oncology Research

Acute Myeloid Leukemia (AML) Whole Blood is collected from IRB-consented donors with a clinically confirmed AML diagnosis and shipped same day. AML is an aggressive myeloid neoplasm in which transformed haematopoietic progenitors lose the capacity to differentiate and accumulate as blasts in bone marrow and peripheral blood, displacing normal haematopoiesis. Classification and treatment are increasingly driven by recurrent genetic lesions, and these fresh samples support tumour genomics, minimal residual disease methodology and targeted therapy research.

Leukaemic Transformation, Molecular Drivers and Why Whole Blood

• AML is a clonal neoplasm of myeloid progenitors. Blocked differentiation and unchecked proliferation produce circulating blasts, which is what makes peripheral whole blood informative rather than only marrow.
• Recurrent driver lesions define prognostic groups and therapeutic options. FLT3 internal tandem duplications and tyrosine kinase domain mutations, NPM1 mutations, and IDH1/IDH2 mutations each have licensed or investigational targeted agents.
• Cytogenetic abnormalities, including core-binding factor rearrangements and complex karyotypes, remain central to risk stratification alongside molecular findings.
• Blast immunophenotype by multiparameter flow cytometry is used both diagnostically and to define the marker combinations used for measurable residual disease tracking — work that requires viable nucleated cells.
• Whole blood preserves leukaemic blasts, residual normal leukocytes and the plasma compartment together, allowing paired genomic, immunophenotypic and circulating-analyte analysis from one collection.
• Circulating tumour DNA and cell-free nucleic acid approaches to AML monitoring can be developed from the plasma fraction of the same donor sample.

Donor Stratification Available

• Molecular profile where documented: FLT3, NPM1, IDH1/IDH2, CEBPA, TP53
• Cytogenetic risk group where available
• Disease status: newly diagnosed, on treatment, in remission, or relapsed/refractory
• De novo versus secondary AML arising from a prior myeloid neoplasm
• Treatment history: intensive chemotherapy, hypomethylating agents, venetoclax-based regimens, targeted inhibitors, or prior transplant
• Matched healthy controls available

Product Features

• Fresh whole blood from clinically diagnosed AML donors
• Custom anticoagulants and collection tubes available
• Same-day collection and shipment
• Custom volumes available on request
• Research Use Only (RUO)

De-identified Donor Data

• Physician-confirmed AML diagnosis, including FLT3/NPM1/IDH1/IDH2 status where available
• Demographics: age, sex assigned at birth, ethnicity
• Relevant medical and treatment history
• Disease status at collection and blast percentage where documented

Applications

• FLT3, NPM1 and IDH1/IDH2 mutation detection assay development
• Measurable residual disease methodology development by flow cytometry and molecular methods
• Blast immunophenotyping and leukaemia-associated immunophenotype characterisation
• Targeted inhibitor sensitivity and resistance research in primary cells
• Bulk and single-cell transcriptomic profiling of leukaemic and residual normal populations
• Circulating tumour DNA and cell-free nucleic acid assay development
• Immuno-oncology target discovery, including AML surface antigen and CAR-T target validation
• Tumour immunology and T cell exhaustion profiling in the leukaemic setting

Other Acute Myeloid Leukemia Specimen Types

• Acute Myeloid Leukemia PBMC
• Acute Myeloid Leukemia Plasma
• Acute Myeloid Leukemia Serum

Looking for the lymphoblastic form? See our Acute Lymphoblastic Leukemia Whole Blood product, or our Myelodysplastic Syndrome Whole Blood for related myeloid neoplasms.

Compliance and Quality Assurance

• IRB-approved protocols and electronic informed consent
• HIPAA-compliant donor data handling

Ordering & Customization

AML whole blood is available in standard and custom volumes. For pricing, current availability, international orders or documentation requirements, email learnmore@sanguinebio.com. To browse donor cohorts across our full inventory, visit our human whole blood page.